FREMONT, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage
biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All
of the shares to be sold in the offering will be offered by Zosano. In addition, Zosano intends to grant to the underwriter a
30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same
terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when
the offering may be completed, or the actual size or terms of the offering.
Zosano intends to use the net proceeds from the offering to fund its ongoing development and preparation for potential
commercialization of Qtrypta™ (M207), and for working capital and general corporate purposes.
Cantor Fitzgerald & Co. is the sole book-running manager for the proposed offering.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and
became effective on March 27, 2019. The offering is being made only by means of a written prospectus and prospectus supplement that
will form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the
offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Alternatively, copies of the
preliminary prospectus supplement and the accompanying prospectus, when available, may be obtained from Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or jurisdiction.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing administration of therapeutics to
patients using its intracutaneous delivery system, which consists of titanium microneedles coated with drug that can enable rapid
systemic administration to patients. The company’s lead product candidate is Qtrypta™ (M207), which is Zosano’s proprietary
formulation of zolmitriptan delivered via its intracutaneous delivery technology for the treatment of migraine disease. In February
2017, the company announced statistically significant results from the ZOTRIP pivotal study and in February 2019, Zosano announced
the completion of the final milestone in its long-term safety study.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Zosano, they
are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of
the Private Securities Litigation Reform Act of 1995, including Zosano’s expected use of the proceeds of the proposed public
offering. Such forward-looking statements involve substantial risks and uncertainties that could cause Zosano’s future results,
performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering
on the anticipated terms or at all. Zosano undertakes no obligation to update or revise any forward-looking statements. For a
further description of the risks and uncertainties that could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Zosano’s business in general, please refer to Zosano’s prospectus
supplement to be filed with the SEC, including the documents incorporated by reference therein, which include Zosano’s Annual
Report on Form 10-K filed with the SEC on March 25, 2019, and Zosano’s other periodic reports filed with the SEC.
Zosano Contact:
Greg Kitchener
Chief Financial Officer
(510) 745-1200
PR Contact:
Sylvia Wheeler and Alexandra Santos
swheeler@wheelhouselsa.com/asantos@wheelhouselsa.com
